Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lipokraft is an autologous adipose-derived stem cell therapy developed by StemGenn Therapeutics. The therapy utilizes a patient's own fat tissue, which is processed to isolate adipose-derived stem cells and is often combined with concentrated plasma (O-Cell PRP). This combination is designed to populate regions of scar tissue or degenerative areas with new living cells to promote natural healing and tissue regeneration. It is primarily used in regenerative medicine for skin rejuvenation, scar reduction, stretch mark treatment, and various degenerative conditions. The mechanism of action relies on the multipotent regenerative potential of adipose-derived stem cells, which have the ability to replicate and differentiate into various cell types to recharge and revitalize damaged tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lipokraft.